Literature DB >> 10764430

Role of isolated locoregional recurrence of breast cancer: results of four prospective studies.

C Schmoor1, W Sauerbrei, G Bastert, M Schumacher.   

Abstract

PURPOSE: We evaluated the effect on future prognosis of an isolated locoregional recurrence (ILRR) after the primary diagnosis of breast cancer. Using data from four prospective studies of the German Breast Cancer Study Group, we investigated factors influencing prognosis after ILRR and defined a simple classification of patients into groups with different prognoses. PATIENTS AND METHODS: From 1983 to 1989, 2,746 patients were recruited into four studies comparing different treatments in primary breast cancer. After a median follow-up time of 8 years, 337 patients developed an ILRR as the first event. The influence of ILRRs on disease progression was examined. The effects of different prognostic factors on progression-free survival (PFS) and overall survival after ILRR were analyzed after a median follow-up time of 4.5 years.
RESULTS: ILRRs increased the risk with respect to distant recurrence and death. After ILRR, 185 events occurred with respect to the PFS end point, and 171 patients died. Primary nodal status, tumor grade, estrogen receptor status of the primary tumor, and length of the disease-free interval (DFI) until the time of the ILRR had a significant prognostic impact.
CONCLUSION: Determinants of prognosis after the ILRR should be taken into account for designing future risk-adapted clinical studies for these patients. Risk strata can be defined by a simple classification scheme based on primary nodal status and DFI.

Entities:  

Mesh:

Year:  2000        PMID: 10764430     DOI: 10.1200/JCO.2000.18.8.1696

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  26 in total

1.  Resection of Primary and Secondary Tumors of the Sternum: An Analysis of Prognostic Variables.

Authors:  Usman Ahmad; Haoxian Yang; Camelia Sima; Daniel H Buitrago; R Taylor Ripley; Kei Suzuki; Manjit S Bains; Nabil P Rizk; Valerie W Rusch; James Huang; Prasad S Adusumilli; Gaetano Rocco; David R Jones
Journal:  Ann Thorac Surg       Date:  2015-05-20       Impact factor: 4.330

2.  Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

Authors:  R Kreienberg; U-S Albert; M Follmann; I B Kopp; T Kühn; A Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-06       Impact factor: 2.915

Review 3.  Role of radiation therapy in palliative care of the patient with cancer.

Authors:  Stephen T Lutz; Joshua Jones; Edward Chow
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

4.  Scintimammography in conjunction with ultrasonography for local breast cancer recurrence in post-mastectomy breast.

Authors:  S Usmani; H Khan; N Ahmed; F Marafi; N Garvie
Journal:  Br J Radiol       Date:  2010-11       Impact factor: 3.039

Review 5.  Hyperthermia combined with radiation therapy for superficial breast cancer and chest wall recurrence: a review of the randomised data.

Authors:  Timothy M Zagar; James R Oleson; Zeljko Vujaskovic; Mark W Dewhirst; Oana I Craciunescu; Kimberly L Blackwell; Leonard R Prosnitz; Ellen L Jones
Journal:  Int J Hyperthermia       Date:  2010       Impact factor: 3.914

6.  Local relapse after breast-conserving surgery and radiotherapy: effects on survival parameters.

Authors:  Josef Hammer; Christine Track; Dietmar H Seewald; Kurt J Spiegl; Johannes Feichtinger; Andreas L Petzer; Werner Langsteger; Sabine Pöstlberger; Elisabeth Bräutigam
Journal:  Strahlenther Onkol       Date:  2009-08-28       Impact factor: 3.621

7.  Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.

Authors:  Jonathan Karnon; Thomas Delea; Stephen R D Johnston; Robert Smith; Jane Brandman; Jennifer Sung; Paul E Goss
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

8.  The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.

Authors:  Gerardus W J Frederix; Johan G C van Hasselt; Jan H M Schellens; Anke M Hövels; Jan A M Raaijmakers; Alwin D R Huitema; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

9.  Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide.

Authors:  Peng Liubao; Wan Xiaomin; Tan Chongqing; Jon Karnon; Chen Gannong; Li Jianhe; Cui Wei; Luo Xia; Cao Junhua
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Cellular dormancy in minimal residual disease following targeted therapy.

Authors:  Jason R Ruth; Dhruv K Pant; Tien-Chi Pan; Hans E Seidel; Sanjeethan C Baksh; Blaine A Keister; Rita Singh; Christopher J Sterner; Suzanne J Bakewell; Susan E Moody; George K Belka; Lewis A Chodosh
Journal:  Breast Cancer Res       Date:  2021-06-04       Impact factor: 8.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.